血友病治疗市场：按产品类型、分销渠道、地区 - 规模、份额、展望、机会分析，2023-2030 年

血友病是一种遗传性出血性疾病，其中称为凝血因子的蛋白质缺乏或水平低，例如凝血因子 VIII。 大约有 13 种凝血因子，它们与血小板一起作用以凝结血液。 血友病分为 A、B 和 C 三种类型，其中 A 型血友病最常见，由凝血因子 VIII 缺乏引起。 血友病 B 是由因子 IX 缺乏引起的，血友病 C 是由因子 XI 缺乏引起的。 在大多数情况下，血友病是通过家庭成员遗传的。 它主要遗传给男孩。 血友病的主要治疗方法是静脉内补充血液中的凝血因子。 然而，血友病治疗的高成本、药物短缺以及与血浆衍生产品相关的严重不良事件预计会阻碍市场增长。 因此，预计血友病的发病率和患病率将上升，从而推动预测期内市场的增长。 这导致各大公司推出产品以满足消费者未被满足的需求。 有关产品发布和治疗的有利监管情景和指南也有望在预测期内推动市场增长。

市场动态

政府加大对血友病治疗的投入，预计将在预测期内推动血友病治疗市场的增长。 例如，根据 2021 年 6 月在国家医学图书馆发表的一篇文章，世界血友病联合会 (WFH) 开始通过人道主义援助计划在低收入和中等收入国家分发凝血因子浓缩物和 emicizumab。 该计划旨在改善发展中国家数量有限的 PWH 的生活。

这项研究的主要特点

• 本报告对全球血友病药物市场进行了深入分析，包括以 2022 年为基准年的预测期（2023-2030 年）的市场规模（美国）和復合年增长率 (CAGR)。已发布.
• 它阐明了各个细分市场的潜在收入机会，并概述了该市场具有吸引力的投资建议矩阵。
• 它还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
• 本文根据以下参数介绍了全球血友病治疗市场的主要参与者：公司概况、产品组合、主要亮点、财务业绩和战略。
• 本研究涵盖的主要公司包括武田製药有限公司、赛诺菲 S.A.、Octapharma AG、瑞典孤儿 Biovitrum AB、百特国际公司、百健公司、拜耳公司、CSL Behring、Ferring B.V.、辉瑞, Inc.、Kedrion、Novo Nordisk A/S 和 F. Hoffmann-La Roche AG。
• 从这份报告中获得的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。.
• 血友病治疗全球市场报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过用于分析全球血友病治疗市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场范围

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 按产品类型划分的市场概况
  • 市场概况：按分销渠道
  • 市场概况：按地区
• 连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

• 市场动态
  • 司机
  • 约束因素
  • 市场机会
• 影响分析
• 最近的产品发布状态
• 流行病学
• 合併/收购/合作
• 监管场景
• 主要发展
• 害虫分析

第 4 章全球血友病药物市场 - 冠状病毒 (COVID-19) 大流行的影响

• 经济影响
• COVID-19 流行病学
• 对供需的影响

第 5 章全球血友病药物市场（按产品类型）：2017-2030

• 重组凝血因子
• 血浆衍生凝血因子
• 抗纤维蛋白溶解药
• 去氨加压素

第 6 章全球血友病药物市场（按分销渠道）：2017-2030

• 医院药房
• 零售药房
• 在线药店

第 7 章。全球血友病药物市场：地区，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 其他亚太地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第八章竞争格局

• Takeda Pharmaceutical Co., Ltd.
• Sanofi S.A.
• Octapharma AG
• Swedish Orphan Biovitrum AB
• Baxter International Inc.
• Biogen Inc.
• Bayer AG
• CSL Behring
• Ferring B.V.
• Pfizer, Inc.
• Kedrion
• Novo Nordisk A/S
• F. Hoffmann-La Roche AG

第 9 章

• 调查方法
• 关于出版商

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor such as factor VIII. There are around 13 types of clotting factors that work with blood platelets to help in clotting of blood. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency of factor VIII. Hemophilia B occurs due to deficiency of factor IX, and Hemophilia C is caused due to factor XI deficiency.In most cases, hemophilia is passed down through families that are inherited. It is mostly passed to the male childrens. The primary treatment for hemophilia is to replace the clotting factor in the blood though intravenous infusions. However, high cost of hemophilia treatment, lack of medicines and serious adverse events associated with plasma derived derived products is expected to hinder the market growth. Consequently, rising incidence and prevalence of hemophilic disorders are expected to boost growth of the market over the forecast period. This has led to product launches by key players to fulfill the unmet needs of consumers. Favorable regulatory scenarios and guidelines for the product launches and treatment are other factors that are expected to propel growth of the market over the forecast period.

Market Dynamics

Increasing government initiatives towards hemophilia treatment is likely expected to propel the growth of hemophilia treatment market over the forecast period. For instance, according to the article published in National Library of Medicine in June 2021, World Federation of Hemophilia(WFH) started distribution of coagulation factor concentrates and emicizumab in low- and low-middle-income countries through a humanitarian aid program. This programwill hwlp to improve life of a limited number of PWH in the developing world.

Key features of the study:

• This report provides an in-depth analysis of the global hemophilia treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hemophilia treatment market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Takeda Pharmaceutical Co., Ltd., Sanofi S.A., Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, and F. Hoffmann-La Roche AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global hemophilia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemophilia treatment market

Detailed Segmentation:

• Global Hemophilia Treatment Market, By Product Type:
  • Plasma Derived Coagulation Factor
  • Recombinant Coagulation Factor
  • Antifibrinolytic Agents
  • Desmopressin
• Global Hemophilia Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Hemophilia Treatment Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country:
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Takeda Pharmaceutical Co., Ltd*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Sanofi S.A.
  • Octapharma AG
  • Swedish Orphan Biovitrum AB
  • Baxter International Inc.
  • Biogen Inc
  • Bayer AG
  • CSL Behring
  • Ferring B.V.
  • Pfizer, Inc.
  • Kedrion
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche AG

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Recent Product Launches
• Epidemiology
• Merger, Acquisition, and Collaborations
• Regulatory Scenario
• Key Developments
• PEST Analysis

4. Global Hemophilia Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact on Supply and Demand

5. Global Hemophilia Treatment Market, By Product Type, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017- 2030
  • Segment Trends
• Recombinant Coagulation Factor
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Plasma Derived Coagulation Factor
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Antifibrinolytic Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Desmopressin
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. Global Hemophilia Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. Global Hemophilia Treatment Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2023 and 2030 (%)
  • Y-o-Y Growth Analysis, For Region, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

8. Competitive Landscape

• Takeda Pharmaceutical Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Sanofi S.A.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Octapharma AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Swedish Orphan Biovitrum AB
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Baxter International Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Biogen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• CSL Behring
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Ferring B.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Kedrion
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novo Nordisk A/S
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

9. Section

• Research Methodology
• About Us